Dr. Devalingam Mahalingam, MD

Dr. Mahalingam practices at Northwestern Medical Group in Chicago, Illinois.

Dr. Mahalingam's NPI, 1164650859, was assigned on July 1, 2009. Dr. Mahalingam holds Illinois license 036-142503.

Dr. Mahalingam's primary practice is Northwestern Medical Group, at 675 N St Clair St, Chicago, IL 60611 in Cook County. The practice phone is (312) 695-0646.

Dr. Mahalingam's primary practice is Northwestern Medical Group in Chicago, Illinois. Dr. Mahalingam is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Mahalingam to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mahalingam practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Mahalingam's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Mahalingam's licenses on file in 2 states: Illinois and Texas.

CMS data shows 58,985 Medicare services from Dr. Mahalingam across 41 procedure codes in 2024, for 384 Medicare patients. Medicare paid $1,388,255 for them.

CMS counts 384 Medicare patients who saw Dr. Mahalingam in 2024. The largest group is 65 to 74, with 176 patients. 68% of them have high blood pressure, and 66% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mahalingam's median patient age at 71, with 46% women.

In 2024, Dr. Mahalingam wrote 194 Medicare Part D claims for 52 patients. 63% of them were for generic drugs. CMS names the drug for 94 of them, across 4 drugs with 11 or more claims each, at $297,281 in total drug cost. In 2023, CMS named 69 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Mahalingam for performance year 2024, reported through an alternative payment model (APM). Dr. Mahalingam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mahalingam as offering telehealth.

Dmand AI links 76 papers to Dr. Mahalingam, published from 2012 to 2025. 2019 was the busiest year, with 8. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms and Liver Neoplasms. Dr. Mahalingam has published most often in Cancers (Basel). Dr. Mahalingam's most frequent co-authors are John Sarantopoulos, MD, Mary F. Mulcahy, MD and Sukeshi Patel Arora, MD.

CMS Open Payments shows 546 general payments to Dr. Mahalingam from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 57% of the total. Amgen Inc. paid the most, $135,165. It also lists 1 research payment totaling $18,183 in 2022.